Your browser doesn't support javascript.
loading
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos, Meletios A; Terpos, Evangelos; Boccadoro, Mario; Delimpasi, Sosana; Beksac, Meral; Katodritou, Eirini; Moreau, Philippe; Baldini, Luca; Symeonidis, Argiris; Bila, Jelena; Oriol, Albert; Mateos, Maria-Victoria; Einsele, Hermann; Orfanidis, Ioannis; Ahmadi, Tahamtan; Ukropec, Jon; Kampfenkel, Tobias; Schecter, Jordan M; Qiu, Yanping; Amin, Himal; Vermeulen, Jessica; Carson, Robin; Sonneveld, Pieter.
Afiliación
  • Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: mdimop@med.uoa.gr.
  • Terpos E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Boccadoro M; Division of Hematology, University of Torino, Turin, Italy.
  • Delimpasi S; Department of Hematology, Evangelismos Hospital, Athens, Greece.
  • Beksac M; Department of Hematology, Ankara University, Ankara, Turkey.
  • Katodritou E; Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece.
  • Moreau P; Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
  • Baldini L; UO Ematologia, Fondazione IRCCS Cà Granda, OM Policlinico, Università degli Studi, Milan, Italy.
  • Symeonidis A; Department of Internal Medicine, University of Patras, Patras, Greece.
  • Bila J; Clinic of Hematology, University of Belgrade, Belgrade, Serbia.
  • Oriol A; Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona, Spain.
  • Mateos MV; Hematology Department, University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Einsele H; Department of Medicine II, Würzburg University Medical Centre, Würzburg, Germany.
  • Orfanidis I; Health Data Specialists, Dublin, Ireland.
  • Ahmadi T; Genmab US, Princeton, NJ, USA.
  • Ukropec J; Janssen Global Medical Affairs, Horsham, PA, USA.
  • Kampfenkel T; Janssen Research and Development, Leiden, Netherlands.
  • Schecter JM; Janssen Research and Development, Raritan, NJ, USA.
  • Qiu Y; Janssen Research and Development, Beijing, China.
  • Amin H; Janssen Research and Development, Raritan, NJ, USA.
  • Vermeulen J; Janssen Research and Development, Leiden, Netherlands.
  • Carson R; Janssen Research and Development, Spring House, PA, USA.
  • Sonneveld P; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands.
Lancet Oncol ; 22(6): 801-812, 2021 06.
Article en En | MEDLINE | ID: mdl-34087126
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Talidomida / Dexametasona / Anticuerpos Monoclonales / Mieloma Múltiple Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Talidomida / Dexametasona / Anticuerpos Monoclonales / Mieloma Múltiple Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article